GlassScriptPhysician profile
Tarun Aurora
NPI 1578927356
$6,392.02
in general payments reported to CMS, 2019-2025
13 companies · $5,763 in 2025
The $5,763 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.50 · 2022: $17.31 · 2023: $195 · 2024: $369 · 2025: $5,763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,200 · Food and Beverage: $1,020 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,200.00 |
| Food and Beverage | $1,019.93 |
| Education | $107.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $5,200.00 | 2025 | |
| Genetix Biotherapeutics INC | $405.16 | 2025 | Lyfgenia |
| Pfizer INC. | $133.65 | 2024 | |
| Lilly USA, LLC | $133.24 | 2023 | Jaypirca, Verzenio |
| Alexion Pharmaceuticals, INC. | $112.94 | 2025 | Ultomiris |
| Sobi, INC | $102.68 | 2024 | |
| Genzyme Corporation | $97.04 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $80.99 | 2024-2025 | |
| Seagen INC. | $47.50 | 2021 | |
| Adaptive Biotechnologies Corporation | $26.22 | 2023 | Clonoseq |
| Celgene Corporation | $21.33 | 2023 | Pomalyst |
| Adc Therapeutics America, INC. | $17.31 | 2022 | |
| Depuy Synthes Sales INC. | $13.96 | 2023 | Viper |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarun Aurora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.